Stephen J. Freedland, MD

AddThis

Print

email this


Associate Professor of Surgery
Associate Professor in Pathology
Department / Division:
Surgery / Urology
Address:
DUMC 2626
Durham, NC 27710
Appointment Telephone:
919-668-8108
Office Telephone:
919-668-5946
Fax:
919-668-7093
Training:
  • MD, University of California–Davis School of Medicine, 1997
Residency:
  • General Surgery, University of California–Los Angeles Medical Center, 1997-1999
  • Urology, University of California–Los Angeles Medical Center, 1999-2003
Fellowship:
  • Urologic Oncology, Johns Hopkins Hospital (Maryland), 2003-2005
Clinical Interests:
Prostate cancer, benign prostatic hyperplasia, and other prostate diseases; GreenLight laser prostatectomy; radical prostatectomy; TURP; button TURP
Research Interests:
Prostate cancer
Obesity
Nutrition
Diet
Outcomes and database analyses
Statistical modeling
risk stratification
PSA
Biomarkers
Representative Publications:
  • Freedland, SJ; Giovannucci, E; Platz, EA. Are findings from studies of obesity and prostate cancer really in conflict?. Cancer Causes and Control. 2006;17:5-9.  Abstract
  • Freedland, SJ; Kane, CJ; Amling, CL; Aronson, WJ; Presti, JC; Terris, MK; SEARCH Database Study Group. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. Journal of Urology. 2006;175:1298-1302.  Abstract
  • Freedland, SJ; Partin, AW. Prostate-specific antigen: update 2006. Urology. 2006;67:458-460.  Abstract
  • Freedland, SJ; Platz, EA; Presti, JC; Aronson, WJ; Amling, CL; Kane, CJ; Terris, MK. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. Journal of Urology. 2006;175:500-504.  Abstract
  • Makarov, DV; Humphreys, EB; Mangold, LA; Walsh, PC; Partin, AW; Epstein, JI; Freedland, SJ. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. Journal of Urology. 2006;176:554-558.  Abstract
  • Nielsen, ME; Han, M; Mangold, L; Humphreys, E; Walsh, PC; Partin, AW; Freedland, SJ. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. Journal of Urology. 2006;176:515-519.  Abstract
  • Freedland, SJ. Obesity and prostate cancer: a growing problem. Clinical Cancer Research. 2005;11:6763-6766.  Abstract
  • Freedland, SJ; Aronson, WJ. Obesity and prostate cancer. Urology. 2005;65:433-439.  Abstract
  • Freedland, SJ; Grubb, KA; Yiu, SK; Humphreys, EB; Nielsen, ME; Mangold, LA; Isaacs, WB; Partin, AW. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. Journal of Urology. 2005;174:919-922.  Abstract
  • Freedland, SJ; Grubb, KA; Yiu, SK; Nielsen, ME; Mangold, LA; Isaacs, WB; Epstein, JI; Partin, AW. Obesity and capsular incision at the time of open retropubic radical prostatectomy. Journal of Urology. 2005;174:1798-1801.  Abstract
  • Freedland, SJ; Haffner, MC; Landis, PK; Saigal, CS; Carter, HB. Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy. Urology. 2005;65:1131-1136.  Abstract
  • Freedland, SJ; Humphreys, EB; Mangold, LA; Eisenberger, M; Dorey, FJ; Walsh, PC; Partin, AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA: Journal of the American Medical Association. 2005;294:433-439.  Abstract
  • Freedland, SJ; Isaacs, WB. Explaining racial differences in prostate cancer in the United States: sociology or biology?. The Prostate. 2005;62:243-252.  Abstract
  • Freedland, SJ; Isaacs, WB; Mangold, LA; Yiu, SK; Grubb, KA; Partin, AW; Epstein, JI; Walsh, PC; Platz, EA. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clinical Cancer Research. 2005;11:2883-2888.  Abstract
  • Freedland, SJ; Isaacs, WB; Platz, EA; Terris, MK; Aronson, WJ; Amling, CL; Presti, JC; Kane, CJ. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. Journal of Clinical Oncology. 2005;23:7546-7554.  Abstract
  • Freedland, SJ; Mangold, LA; Walsh, PC; Partin, AW. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. Journal of Urology. 2005;174:1276-1281.  Abstract
  • Freedland, SJ; Terris, MK; Platz, EA; Presti, JC. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology. 2005;66:108-113.  Abstract
  • Haffner, MC; Landis, PK; Saigal, CS; Carter, HB; Freedland, SJ. Health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy in the phosphodiesterase type 5 ERA: impact of neurovascular bundle preservation. Urology. 2005;66:371-376.  Abstract
  • Freedland, SJ; Aronson, WJ; Kane, CJ; Presti, JC; Amling, CL; Elashoff, D; Terris, MK. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. Journal of Clinical Oncology. 2004;22:446-453.  Abstract
  • Freedland, SJ; Aronson, WJ; Kane, CJ; Terris, MK; Presti, JC; Trock, B; Amling, CL. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer. 2004;101:748-753.  Abstract
  • Freedland, SJ; Mangold, LA; Epstein, JI; Partin, AW. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease. Urology. 2004;63:887-891.  Abstract
  • Freedland, SJ; Partin, AW; Epstein, JI; Walsh, PC. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer. 2004;100:1646-1649.  Abstract
  • Freedland, SJ; Presti, JC; Kane, CJ; Aronson, WJ; Terris, MK; Dorey, F; Amling, CL; SEARCH Database Study Group. Do younger men have better biochemical outcomes after radical prostatectomy?. Urology. 2004;63:518-522.  Abstract
  • Freedland, SJ; Terris, MK; Csathy, GS; Kane, CJ; Amling, CL; Presti, JC; Dorey, F; Aronson, WJ; Search Database Study Group. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. Journal of Urology. 2004;171:2215-2220.  Abstract
  • Freedland, SJ; Terris, MK; Presti, JC; Amling, CL; Kane, CJ; Trock, B; Aronson, WJ; Search Database Study Group. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. Journal of Urology. 2004;172:520-524.  Abstract
  • Ngo, TH; Barnard, RJ; Anton, T; Tran, C; Elashoff, D; Heber, D; Freedland, SJ; Aronson, WJ. Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. Cancer Research. 2004;64:1252-1254.  Abstract
  • Okotie, OT; Aronson, WJ; Wieder, JA; Liao, Y; Dorey, F; DeKERNION, JB; Freedland, SJ. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. Journal of Urology. 2004;171:2260-2264.  Abstract
  • Freedland, SJ; Aronson, W; Presti, JC; Kane, CJ; Terris, MK; Elashoff, D; Amling, CL; SEARCH Database Study Group. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. Journal of Urology. 2003;169:2142-2146.  Abstract
  • Freedland, SJ; Aronson, WJ; Terris, MK; Kane, CJ; Amling, CL; Dorey, F; Presti, JC; SEARCH Database Study Group. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. Journal of Urology. 2003;169:2136-2141.  Abstract
  • Freedland, SJ; Presti, JC; Amling, CL; Kane, CJ; Aronson, WJ; Dorey, F; Terris, MK; SEARCH Database Study Group. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736-741.  Abstract
  • Freedland, SJ; Presti, JC; Terris, MK; Kane, CJ; Aronson, WJ; Dorey, F; Amling, CL; SEARCH Database Study Group. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. Journal of Urology. 2003;169:2129-2135.  Abstract
  • Freedland, SJ; Sutter, ME; Dorey, F; Aronson, WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003;61:365-369.  Abstract
  • Freedland, SJ; Amling, CL; Dorey, F; Kane, CJ; Presti, JC; Terris, MK; Aronson, WJ; Shared Equal Access Regional Cancer Hospital Database Study Group. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002;60:670-674.  Abstract
  • Freedland, SJ; Csathy, GS; Dorey, F; Aronson, WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. Journal of Urology. 2002;167:516-520.  Abstract
  • Freedland, SJ; Jalkut, M; Dorey, F; Sutter, ME; Aronson, WJ. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology. 2000;56:87-91.  Abstract
  • Freedland, SJ; Sutter, ME; Naitoh, J; Dorey, F; Csathy, GS; Aronson, WJ. Clinical characteristics in black and white men with prostate cancer in an equal access medical center. Urology. 2000;55:387-390.  Abstract